Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 167Neoplasms 30Neoplasm Metastasis 29Brain Neoplasms 16Breast Neoplasms, Male 15Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Colorectal Neoplasms 6Prostatic Neoplasms 5Inflammatory Breast Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Gallbladder Neoplasms 3Ependymoma 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Solid Tumors 2Osteitis Deformans 2

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Lapatinib × Clear all
NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡